Cargando…

Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice

Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway that involves inhibition of salt-inducible kinase isoforms 2 and 3 (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Tadatoshi, Andrade, Christian D. Castro, Yoon, Sung-Hee, Zhao, Yingshe, Greenlee, William J., Weber, Patricia C., Viswanathan, Usha, Kulp, John, Brooks, Daniel J., Demay, Marie B., Bouxsein, Mary L., Mitlak, Bruce, Lanske, Beate, Wein, Marc N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897432/
https://www.ncbi.nlm.nih.gov/pubmed/36472957
http://dx.doi.org/10.1073/pnas.2214396119
_version_ 1784882248438251520
author Sato, Tadatoshi
Andrade, Christian D. Castro
Yoon, Sung-Hee
Zhao, Yingshe
Greenlee, William J.
Weber, Patricia C.
Viswanathan, Usha
Kulp, John
Brooks, Daniel J.
Demay, Marie B.
Bouxsein, Mary L.
Mitlak, Bruce
Lanske, Beate
Wein, Marc N.
author_facet Sato, Tadatoshi
Andrade, Christian D. Castro
Yoon, Sung-Hee
Zhao, Yingshe
Greenlee, William J.
Weber, Patricia C.
Viswanathan, Usha
Kulp, John
Brooks, Daniel J.
Demay, Marie B.
Bouxsein, Mary L.
Mitlak, Bruce
Lanske, Beate
Wein, Marc N.
author_sort Sato, Tadatoshi
collection PubMed
description Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway that involves inhibition of salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3). Here, we further validate SIK2/SIK3 as osteoporosis drug targets by demonstrating that ubiquitous deletion of these genes in adult mice increases bone formation without extraskeletal toxicities. Previous efforts to target these kinases to stimulate bone formation have been limited by lack of pharmacologically acceptable, specific, orally available SIK2/SIK3 inhibitors. Here, we used structure-based drug design followed by iterative medicinal chemistry to identify SK-124 as a lead compound that potently inhibits SIK2 and SIK3. SK-124 inhibits SIK2 and SIK3 with single-digit nanomolar potency in vitro and in cell-based target engagement assays and shows acceptable kinome selectivity and oral bioavailability. SK-124 reduces SIK2/SIK3 substrate phosphorylation levels in human and mouse cultured bone cells and regulates gene expression patterns in a PTH-like manner. Once-daily oral SK-124 treatment for 3 wk in mice led to PTH-like effects on mineral metabolism including increased blood levels of calcium and 1,25-vitamin D and suppressed endogenous PTH levels. Furthermore, SK-124 treatment increased bone formation by osteoblasts and boosted trabecular bone mass without evidence of short-term toxicity. Taken together, these findings demonstrate PTH-like effects in bone and mineral metabolism upon in vivo treatment with orally available SIK2/SIK3 inhibitor SK-124.
format Online
Article
Text
id pubmed-9897432
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher National Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-98974322023-02-04 Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice Sato, Tadatoshi Andrade, Christian D. Castro Yoon, Sung-Hee Zhao, Yingshe Greenlee, William J. Weber, Patricia C. Viswanathan, Usha Kulp, John Brooks, Daniel J. Demay, Marie B. Bouxsein, Mary L. Mitlak, Bruce Lanske, Beate Wein, Marc N. Proc Natl Acad Sci U S A Biological Sciences Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway that involves inhibition of salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3). Here, we further validate SIK2/SIK3 as osteoporosis drug targets by demonstrating that ubiquitous deletion of these genes in adult mice increases bone formation without extraskeletal toxicities. Previous efforts to target these kinases to stimulate bone formation have been limited by lack of pharmacologically acceptable, specific, orally available SIK2/SIK3 inhibitors. Here, we used structure-based drug design followed by iterative medicinal chemistry to identify SK-124 as a lead compound that potently inhibits SIK2 and SIK3. SK-124 inhibits SIK2 and SIK3 with single-digit nanomolar potency in vitro and in cell-based target engagement assays and shows acceptable kinome selectivity and oral bioavailability. SK-124 reduces SIK2/SIK3 substrate phosphorylation levels in human and mouse cultured bone cells and regulates gene expression patterns in a PTH-like manner. Once-daily oral SK-124 treatment for 3 wk in mice led to PTH-like effects on mineral metabolism including increased blood levels of calcium and 1,25-vitamin D and suppressed endogenous PTH levels. Furthermore, SK-124 treatment increased bone formation by osteoblasts and boosted trabecular bone mass without evidence of short-term toxicity. Taken together, these findings demonstrate PTH-like effects in bone and mineral metabolism upon in vivo treatment with orally available SIK2/SIK3 inhibitor SK-124. National Academy of Sciences 2022-12-06 2022-12-13 /pmc/articles/PMC9897432/ /pubmed/36472957 http://dx.doi.org/10.1073/pnas.2214396119 Text en Copyright © 2022 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Biological Sciences
Sato, Tadatoshi
Andrade, Christian D. Castro
Yoon, Sung-Hee
Zhao, Yingshe
Greenlee, William J.
Weber, Patricia C.
Viswanathan, Usha
Kulp, John
Brooks, Daniel J.
Demay, Marie B.
Bouxsein, Mary L.
Mitlak, Bruce
Lanske, Beate
Wein, Marc N.
Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
title Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
title_full Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
title_fullStr Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
title_full_unstemmed Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
title_short Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
title_sort structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
topic Biological Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897432/
https://www.ncbi.nlm.nih.gov/pubmed/36472957
http://dx.doi.org/10.1073/pnas.2214396119
work_keys_str_mv AT satotadatoshi structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT andradechristiandcastro structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT yoonsunghee structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT zhaoyingshe structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT greenleewilliamj structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT weberpatriciac structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT viswanathanusha structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT kulpjohn structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT brooksdanielj structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT demaymarieb structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT bouxseinmaryl structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT mitlakbruce structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT lanskebeate structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice
AT weinmarcn structurebaseddesignofselectiveorallyavailablesaltinduciblekinaseinhibitorsthatstimulateboneformationinmice